Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Nanoviricides 10-Q Filed Monday Afternoon Showed Q3 EPS $(0.16) Up From $(0.19) YoY

Nanoviricides (AMEX:NNVC) reported quarterly losses of $(0.16) per share. This is a 15.79 percent increase over losses of $(0.19) per share from the same period last year.
byBenzinga Newsdesk
May 17, 2022
1 minute read
Total
0
Shares
0
0
0
0
0
0

Nanoviricides (AMEX:NNVC) reported quarterly losses of $(0.16) per share. This is a 15.79 percent increase over losses of $(0.19) per share from the same period last year.

 
Total
0
Shares
Share 0
Tweet 0
Share 0
Share 0
Share 0
Share 0
Related Posts
Read More

Atea Pharmaceuticals Announced The Presentation Of New Phase 1, In Vitro And In Vivo Data That Demonstrate Key Profile Attributes Of Atea’s Lead Drug Candidate, Bemnifosbuvir, For Covid-19 And Hepatitis C

By Benzinga Newsdesk
Today, 6:36 AM
Low risk for drug-drug interactions with bemnifosbuvir based upon results from in vitro metabolism and transporter studies Bemnifosbuvir retains activity against all SARS-CoV-2 variants of concern evaluated as well as

AVIR